[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "NIS Run 2",
    "section": "",
    "text": "Reference Papers:\n\nSalman et al. 2024\nPersaud et al. 2019\n[Sreenivasan et al. 2022] (https://www.ajconline.org/article/S0002-9149(22)00408-8/abstract)\n\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among inpatient admissions with colorectal cancer.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with colorectal cancer.\nPeripheral Artery Disease Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression models to evaluate the independent association of AMI with in-hospital outcomes in patients with PAD, adjusting for:\n\nDemographics: Age, sex, race, residential income, and insurance.\nMedical History: Cardiac arrhythmia, Anemia, Cerebrovascular disease, Chronic kidney disease, Chronic obstructive pulmonary disease, Diabetes, Dementia, Heart failure, Hypertension, Hyperlipidemia, Myocardial infarction, Peripheral vascular disease, Rheumatoid disease, Valvular heart disease\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "NIS Run 2",
    "section": "",
    "text": "Reference Papers:\n\nSalman et al. 2024\nPersaud et al. 2019\n[Sreenivasan et al. 2022] (https://www.ajconline.org/article/S0002-9149(22)00408-8/abstract)\n\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among inpatient admissions with colorectal cancer.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with colorectal cancer.\nPeripheral Artery Disease Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression models to evaluate the independent association of AMI with in-hospital outcomes in patients with PAD, adjusting for:\n\nDemographics: Age, sex, race, residential income, and insurance.\nMedical History: Cardiac arrhythmia, Anemia, Cerebrovascular disease, Chronic kidney disease, Chronic obstructive pulmonary disease, Diabetes, Dementia, Heart failure, Hypertension, Hyperlipidemia, Myocardial infarction, Peripheral vascular disease, Rheumatoid disease, Valvular heart disease\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "NIS Run 2",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 17,3801\nNormal weight (BMI 20.0-24.9kg/m²) N = 3,2551\nUnderweight (BMI ≤19.9kg/m²) N = 4,3951\nOverweight (BMI 25.0-29.9kg/m²) N = 2,2101\nClass I obesity (BMI 30.0-34.9kg/m²) N = 2,7801\nClass II obesity (BMI 35.0-39.9kg/m²) N = 2,1051\nClass III obesity (BMI ≥40.0kg/m²) N = 2,6351\np-value2\n\n\n\n\nAge, y\n65 (13)\n66 (14)\n67 (14)\n66 (13)\n64 (12)\n62 (13)\n60 (12)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n8,650 (50%)\n1,475 (45%)\n2,310 (53%)\n970 (44%)\n1,315 (47%)\n1,100 (52%)\n1,480 (56%)\n\n\n\n\n    Male\n8,730 (50%)\n1,780 (55%)\n2,085 (47%)\n1,240 (56%)\n1,465 (53%)\n1,005 (48%)\n1,155 (44%)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Asian or Pacific Islander\n580 (3.4%)\n165 (5.1%)\n205 (4.7%)\n100 (4.6%)\n35 (1.3%)\n50 (2.4%)\n25 (1.0%)\n\n\n\n\n    Black\n2,785 (16%)\n560 (17%)\n820 (19%)\n325 (15%)\n305 (11%)\n290 (14%)\n485 (19%)\n\n\n\n\n    Hispanic\n1,715 (10%)\n305 (9.5%)\n360 (8.3%)\n315 (14%)\n330 (12%)\n200 (9.7%)\n205 (7.9%)\n\n\n\n\n    Native American\n115 (0.7%)\n15 (0.5%)\n35 (0.8%)\n5 (0.2%)\n15 (0.6%)\n10 (0.5%)\n35 (1.3%)\n\n\n\n\n    Other\n430 (2.5%)\n85 (2.6%)\n120 (2.8%)\n65 (3.0%)\n80 (2.9%)\n40 (1.9%)\n40 (1.5%)\n\n\n\n\n    White\n11,505 (67%)\n2,080 (65%)\n2,805 (65%)\n1,380 (63%)\n1,955 (72%)\n1,480 (71%)\n1,805 (70%)\n\n\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n0.038\n\n\n    $1 - $51,999\n4,705 (28%)\n810 (26%)\n1,285 (30%)\n565 (26%)\n705 (26%)\n545 (26%)\n795 (31%)\n\n\n\n\n    $52,000 - $65,999\n4,480 (26%)\n790 (25%)\n1,065 (25%)\n575 (27%)\n745 (27%)\n550 (26%)\n755 (29%)\n\n\n\n\n    $66,000 - $87,999\n4,450 (26%)\n825 (26%)\n1,065 (25%)\n615 (29%)\n695 (25%)\n555 (27%)\n695 (27%)\n\n\n\n\n    $88,000 or more\n3,400 (20%)\n750 (24%)\n880 (20%)\n400 (19%)\n585 (21%)\n430 (21%)\n355 (14%)\n\n\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n2,485 (14%)\n545 (17%)\n700 (16%)\n395 (18%)\n290 (10%)\n165 (7.9%)\n390 (15%)\n\n\n\n\n    Medicare\n9,190 (53%)\n1,745 (54%)\n2,580 (59%)\n1,220 (55%)\n1,420 (51%)\n1,015 (48%)\n1,210 (46%)\n\n\n\n\n    Other\n975 (5.6%)\n215 (6.6%)\n230 (5.2%)\n65 (2.9%)\n205 (7.4%)\n110 (5.2%)\n150 (5.7%)\n\n\n\n\n    Private\n4,720 (27%)\n750 (23%)\n885 (20%)\n530 (24%)\n865 (31%)\n810 (39%)\n880 (33%)\n\n\n\n\nNo. of comorbidities\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n    No comorbidities\n15 (&lt;0.1%)\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n5 (0.2%)\n10 (0.4%)\n\n\n\n\n    One comorbidity\n25 (0.1%)\n5 (0.2%)\n5 (0.1%)\n0 (0%)\n0 (0%)\n5 (0.2%)\n10 (0.4%)\n\n\n\n\n    Two or more comorbidities\n17,340 (100%)\n3,250 (100%)\n4,390 (100%)\n2,210 (100%)\n2,780 (100%)\n2,095 (100%)\n2,615 (99%)\n\n\n\n\nCardiac arrhythmia\n3,790 (22%)\n675 (21%)\n840 (19%)\n555 (25%)\n590 (21%)\n495 (24%)\n635 (24%)\n0.095\n\n\nAnemia\n2,795 (16%)\n585 (18%)\n725 (16%)\n370 (17%)\n440 (16%)\n235 (11%)\n440 (17%)\n0.090\n\n\nCerebrovascular disease\n605 (3.5%)\n100 (3.1%)\n205 (4.7%)\n75 (3.4%)\n120 (4.3%)\n55 (2.6%)\n50 (1.9%)\n0.071\n\n\nChronic kidney disease\n2,760 (16%)\n440 (14%)\n635 (14%)\n315 (14%)\n445 (16%)\n355 (17%)\n570 (22%)\n0.003\n\n\nChronic obstructive pulmonary disease\n3,165 (18%)\n510 (16%)\n780 (18%)\n355 (16%)\n500 (18%)\n405 (19%)\n615 (23%)\n0.016\n\n\nDiabetes\n4,665 (27%)\n665 (20%)\n485 (11%)\n560 (25%)\n1,010 (36%)\n835 (40%)\n1,110 (42%)\n&lt;0.001\n\n\nDementia\n620 (3.6%)\n170 (5.2%)\n265 (6.0%)\n55 (2.5%)\n75 (2.7%)\n30 (1.4%)\n25 (0.9%)\n&lt;0.001\n\n\nHeart failure\n2,465 (14%)\n295 (9.1%)\n530 (12%)\n300 (14%)\n400 (14%)\n325 (15%)\n615 (23%)\n&lt;0.001\n\n\nHypertension\n10,345 (60%)\n1,710 (53%)\n1,905 (43%)\n1,395 (63%)\n1,925 (69%)\n1,495 (71%)\n1,915 (73%)\n&lt;0.001\n\n\nHyperlipidemia\n5,655 (33%)\n845 (26%)\n915 (21%)\n785 (36%)\n1,220 (44%)\n875 (42%)\n1,015 (39%)\n&lt;0.001\n\n\nMyocardial infarction\n1,075 (6.2%)\n185 (5.7%)\n275 (6.3%)\n175 (7.9%)\n150 (5.4%)\n120 (5.7%)\n170 (6.5%)\n0.6\n\n\nPeripheral vascular disease\n1,005 (5.8%)\n145 (4.5%)\n360 (8.2%)\n125 (5.7%)\n175 (6.3%)\n130 (6.2%)\n70 (2.7%)\n&lt;0.001\n\n\nRheumatoid disease\n300 (1.7%)\n65 (2.0%)\n60 (1.4%)\n35 (1.6%)\n55 (2.0%)\n30 (1.4%)\n55 (2.1%)\n0.9\n\n\nValvular heart disease\n780 (4.5%)\n170 (5.2%)\n220 (5.0%)\n80 (3.6%)\n135 (4.9%)\n70 (3.3%)\n105 (4.0%)\n0.5\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "NIS Run 2",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nNormal weight (BMI 20.0-24.9kg/m²) N = 3,2551\nUnderweight (BMI ≤19.9kg/m²) N = 4,3951\nOverweight (BMI 25.0-29.9kg/m²) N = 2,2101\nClass I obesity (BMI 30.0-34.9kg/m²) N = 2,7801\nClass II obesity (BMI 35.0-39.9kg/m²) N = 2,1051\nClass III obesity (BMI ≥40.0kg/m²) N = 2,6351\np-value2\n\n\n\n\nDied during hospitalization\n150 (4.6%)\n305 (6.9%)\n65 (2.9%)\n65 (2.3%)\n35 (1.7%)\n90 (3.4%)\n&lt;0.001\n\n\nLength of stay (days)\n6 (3, 11)\n6 (4, 11)\n6 (3, 11)\n5 (3, 9)\n5 (3, 7)\n5 (3, 9)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n57,372 (33,620, 110,302)\n61,748 (32,479, 126,001)\n72,713 (33,997, 129,030)\n69,563 (37,302, 115,777)\n70,016 (39,070, 117,691)\n68,666 (37,983, 122,278)\n0.094\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "NIS Run 2",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1.53\n0.94, 2.48\n0.085\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.72\n0.36, 1.44\n0.3\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n0.70\n0.35, 1.41\n0.3\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n0.45\n0.19, 1.11\n0.084\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n1.12\n0.57, 2.18\n0.7\n\n\nAge, y\n1.02\n1.00, 1.04\n0.053\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.02\n0.71, 1.46\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n1.11\n0.45, 2.74\n0.8\n\n\n    Hispanic\n0.83\n0.31, 2.23\n0.7\n\n\n    Native American\n1.01\n0.11, 9.67\n&gt;0.9\n\n\n    Other\n1.15\n0.33, 4.01\n0.8\n\n\n    White\n0.67\n0.29, 1.55\n0.3\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.30\n0.81, 2.07\n0.3\n\n\n    $66,000 - $87,999\n1.01\n0.62, 1.65\n&gt;0.9\n\n\n    $88,000 or more\n0.71\n0.40, 1.26\n0.2\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n0.80\n0.43, 1.49\n0.5\n\n\n    Other\n2.41\n1.20, 4.84\n0.013\n\n\n    Private\n1.02\n0.57, 1.83\n&gt;0.9\n\n\nCharlson comorbidity index\n1.27\n1.17, 1.38\n&lt;0.001\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.82\n1.18, 2.81\n0.007\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.84\n0.52, 1.35\n0.5\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.50\n0.72, 3.13\n0.3\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.74\n0.42, 1.31\n0.3\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.48, 1.24\n0.3\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.48\n0.29, 0.81\n0.006\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.46\n0.71, 3.02\n0.3\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.58, 1.82\n&gt;0.9\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.52, 1.15\n0.2\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.90\n0.58, 1.40\n0.6\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.42, 2.03\n0.9\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.57\n0.24, 1.33\n0.2\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.24\n0.34, 4.57\n0.7\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.74\n0.29, 1.87\n0.5\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "NIS Run 2",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n0.60\n-0.36, 1.6\n0.2\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.36\n-0.64, 1.4\n0.5\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n-0.87\n-1.8, 0.11\n0.082\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-1.8\n-2.7, -0.89\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-0.35\n-1.4, 0.69\n0.5\n\n\nAge, y\n-0.02\n-0.06, 0.01\n0.2\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.00\n-0.59, 0.58\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n0.13\n-1.3, 1.6\n0.9\n\n\n    Hispanic\n-0.62\n-2.0, 0.75\n0.4\n\n\n    Native American\n0.79\n-3.6, 5.2\n0.7\n\n\n    Other\n0.55\n-1.8, 2.9\n0.7\n\n\n    White\n-0.67\n-1.9, 0.55\n0.3\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.07\n-0.71, 0.84\n0.9\n\n\n    $66,000 - $87,999\n0.20\n-0.63, 1.0\n0.6\n\n\n    $88,000 or more\n-0.20\n-1.0, 0.59\n0.6\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-0.56\n-1.9, 0.74\n0.4\n\n\n    Other\n-0.73\n-2.4, 0.93\n0.4\n\n\n    Private\n-0.83\n-2.0, 0.38\n0.2\n\n\nCharlson comorbidity index\n0.09\n-0.08, 0.26\n0.3\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.2\n1.3, 3.0\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.2\n0.36, 2.0\n0.005\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.7\n0.00, 3.4\n0.050\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.59\n-0.45, 1.6\n0.3\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.43\n-1.1, 0.27\n0.2\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.08\n-0.75, 0.59\n0.8\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.04\n-1.4, 1.3\n&gt;0.9\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.1\n0.19, 2.1\n0.019\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.14\n-0.79, 0.51\n0.7\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.99\n-1.6, -0.39\n0.001\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.4\n-2.3, -0.38\n0.007\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.89\n-0.64, 2.4\n0.3\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.67\n-1.1, 2.5\n0.5\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.30\n-1.6, 0.99\n0.6\n\n\n\nAbbreviation: CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nBMI category\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Underweight (BMI ≤19.9kg/m²)\n13,007\n809, 25,204\n0.037\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n8,234\n-6,258, 22,725\n0.3\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n2,747\n-9,011, 14,505\n0.6\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-6,372\n-18,992, 6,249\n0.3\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n9,143\n-6,185, 24,470\n0.2\n\n\nAge, y\n-601\n-1,165, -36\n0.037\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n-635\n-8,699, 7,429\n0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    Asian or Pacific Islander\n—\n—\n\n\n\n\n    Black\n-34,069\n-60,390, -7,749\n0.011\n\n\n    Hispanic\n6,552\n-25,123, 38,227\n0.7\n\n\n    Native American\n-33,884\n-76,752, 8,984\n0.12\n\n\n    Other\n-9,313\n-53,618, 34,993\n0.7\n\n\n    White\n-42,096\n-66,219, -17,973\n&lt;0.001\n\n\nIncome quartile\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-3,729\n-14,205, 6,747\n0.5\n\n\n    $66,000 - $87,999\n5,873\n-6,057, 17,804\n0.3\n\n\n    $88,000 or more\n9,059\n-3,503, 21,620\n0.2\n\n\nInsurance payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n3,102\n-14,036, 20,240\n0.7\n\n\n    Other\n-5,732\n-25,710, 14,245\n0.6\n\n\n    Private\n8,779\n-6,800, 24,358\n0.3\n\n\nCharlson comorbidity index\n-2,891\n-5,244, -538\n0.016\n\n\nCardiac arrhythmia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n27,306\n15,400, 39,213\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n10,913\n-1,172, 22,997\n0.077\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n26,789\n-952, 54,531\n0.058\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n20,526\n3,937, 37,115\n0.015\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n6,188\n-5,176, 17,553\n0.3\n\n\nDiabetes\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3,000\n-5,748, 11,747\n0.5\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-14,067\n-30,791, 2,656\n0.10\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n22,381\n5,735, 39,027\n0.008\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-4,675\n-13,803, 4,453\n0.3\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-12,114\n-20,564, -3,664\n0.005\n\n\nMyocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-7,262\n-23,131, 8,606\n0.4\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n12,569\n-10,375, 35,513\n0.3\n\n\nRheumatoid disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n6,423\n-15,754, 28,601\n0.6\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1,579\n-27,925, 24,768\n&gt;0.9\n\n\n\nAbbreviation: CI = Confidence Interval"
  }
]